 SAN DIEGO, Oct. 02, 2021 GLOBE NEWSWIRE -- AnaptysBio, Inc. Nasdaq: ANAB, a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications, today announced that week 16 data from the GPP GALLOP Phase 2 trial of imsidolimab, its investigational anti-interleukin-36 receptor IL-36R therapeutic antibody, was presented at the 2021 European Academy of Dermatology and Venereology EADV Congress. The oral presentation, titled Imsidolimab, an Anti-IL-36 Receptor Monoclonal Antibody, in the Treatment of Generalized Pustular Psoriasis: Results from a Phase 2 Trial, was presented by Dr. Johann Gudjonsson, professor of Dermatology at the University of Michigan. 